Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion criteria:~* Subjects belonging to 3 age groups will be enrolled into the trial: children (24 to 59 months of age at enrollment), older infants (9 to 12 months of age at enrollment) and infants (6 weeks of age at enrolment).~* Written informed consent will be obtained by the parents/ guardians before enrollment into the trial.~* Infants who have been vaccinated with BCG and HBV at birth and OPV at any time since birth can be enrolled into the trial, while infants who have received DTwP+HBV+Hib due at 6 weeks of age as per local EPI schedule cannot be enrolled into the trial.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 59 Months
- Healthy Volunteers: t

Study Arms:
- Vi-CRM, Older infants (Type: EXPERIMENTAL): Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
- PNC13, Older infants (Type: ACTIVE_COMPARATOR): Older infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine
- Vi-CRM, Infants (Type: EXPERIMENTAL): Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine
- PNC13, Infants (Type: ACTIVE_COMPARATOR): Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine
- Vi-CRM, Children (Type: EXPERIMENTAL): Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
- Vi-PS, Children (Type: ACTIVE_COMPARATOR): Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).